Ncardia has developed an iPSC-derived tri-culture approach to support modelling microglia-neuron communication in NDDs. This includes a miniaturized and unique tauopathy assay, through inducing phosphorylation (phospho-Tau) and aggregation of Tau, with recombinant mutant Tau PFFs (pre-formed fibrils). Our approach enables a multi-parametric readout of neuronal and glial phenotypes including microglia activation.
With this platform you can screen your therapeutics’ efficacy in reducing neuroinflammation and neurodegeneration.
Our human iPSC-based platforms combine physiologically relevant models with robust and scalable assays that help you select the best drug candidates and progress with higher confidence.